Related Topics News -

     
 Title only   |   Print 
     
復星醫藥(02196.HK)就復邁寧治療兒童腦膠質瘤啟動Ⅲ期臨床

2025-07-09T  
復星醫藥夥以色列藥企梯瓦共同開發腫瘤免疫療法

2025-06-17T  
《大行》匯豐料國內藥企受惠於對外授權合作 看好恆瑞醫藥及翰森製藥

2025-06-10T  
復星醫藥回購80萬股A股 涉資近2,000萬人幣

2025-06-06T  
復星醫藥曾漲逾一成 子公司復邁寧獲藥品註冊批准

2025-05-30T  
復星醫藥子公司復邁寧獲藥品註冊批准

2025-05-30T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.